-
Sibionics Raises RMB 500 Million in Series D Financing Round
•
Shenzhen-based chronic disease device maker Sibionics has reportedly raised close to RMB 500 million (USD 71.7 million) in a Series D financing round. The round was led by Shanghai Healthcare Capital and Guangdong Traditional Chinese Medicine Healthcare Fund, with contributions from Industrial Securities Capital, Next Capital, and China New Town…
-
Waker Bioscience Raises Angel Funding for ISA Technology Upgrades
•
Waker Bioscience, an integration site analysis (ISA) specialist based in Shanghai, has reportedly raised “tens of millions” of renminbi in an angel financing round, solely led by BGI Co-Win. The proceeds will be used for technology upgrades, team building, testing business development, and laboratory platform automation construction. Company Background and…
-
Ronovo Surgical Raises Pre-Series B Funding for Surgical Robot Development
•
Ronovo Surgical, a minimally invasive surgery device maker based in Shanghai, has reportedly raised “tens of millions” of US dollars in a Pre-Series B financing round led by LongRiver Investments. Other investors included Lilly Asia Ventures, Vivo Capital, Matrix Partners, and GGV Capital. The proceeds will be used for multi-specialty…
-
PingAn Good Doctor Partners to Establish Lifestyle Medicine
•
China-based PingAn Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor, has struck a partnership with the Shenzhen Hospital of Southern Medical University and Shenzhen Community Health Association (SCHA) to establish lifestyle medicine. Financial details of the partnership were not disclosed. PingAn Good Doctor’s ServicesPingAn Good…
-
JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development
•
China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a strategic collaboration with its major shareholder Juno. The deal sees Juno grant licenses to patents and know-how in order to develop, manufacture, and commercialize a chimeric antigen receptor (CAR) T cell therapy targeting the solid…
-
Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm
•
China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the Russian pharmaceutical company Binnopharm Group, focused on 9MW0113, 9MW0321, and 9MW0311, Mabwell’s biosimilar versions of adalimumab and denosumab. Binnopharm will have exclusive rights to develop, register, manufacture, and market the drugs with a status of…
-
Sirnaomics’ Lead Candidate STP707 Shows Promising Phase I Data
•
Sino-US small interfering RNA (siRNA) specialist Sirnaomics (HKG: 2257) has revealed that its lead pipeline candidate STP707 has produced strong early safety and efficacy data in a Phase I clinical trial. STP707, which is comprised of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA and formulated in a peptide nanoparticle…
-
Kira Pharmaceuticals Gains NMPA and TGA Approvals for KP104 Phase II Study
•
Sino-US biotech Kira Pharmaceuticals has announced receiving approvals from China’s National Medical Products Administration (NMPA) and the Australian Therapeutic Goods Administration (TGA) to conduct a Phase II clinical study assessing the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of its KP104 pipeline candidate. This marks a significant milestone in…
-
TowardPi Raises RMB 300 Million in Series C Financing Round
•
China-based ophthalmology device maker TowardPi (Beijing) Medical Technology Ltd has reportedly raised close to RMB 300 million (USD 42.96 million) in a Series C financing round. The round was led by Sunrock Capital, with contributions from Tao Capital, Kunlun Capital, and existing investor Aibo Qingshi Venture Capital. This marks a…
-
Aosaikang Receives FDA Approval for ASKG915 Clinical Trial
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its Category 1 biologic product ASKG915 from the US FDA. The intended indication is advanced solid tumors, marking a significant step forward in the development of innovative therapies for this condition. Drug Profile and DevelopmentASKG915 is…
-
Pfizer Exercises Option for Sisunatovir Rights with LianBio
•
US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise an option to take development and commercialization rights to sisunatovir, a respiratory syncytial virus (RSV) therapeutic candidate, in the territories of mainland China, Hong Kong, Macau, and Singapore. The deal is signed under an earlier…
-
Fosun Pharma Registers Comirnaty Vaccines in Hong Kong
•
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced that Comirnaty (BNT162b2) and Comirnaty bivalent vaccine have been registered as drug/biologic products in Hong Kong. They can now be used as basic immunization for people aged 12 and above, and as a booster shot for people aged 12 and above,…
-
XtalPi Partners with Singapore’s EDDC to Develop Lung Cancer Treatments
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with the Experimental Drug Development Centre (EDDC) of Singapore. The aim is to provide new drug candidates for lung cancer precision treatment, driven by a research and development model integrating artificial intelligence (AI), automation experimentation, and expert expertise. No…
-
CStone’s Sugemalimab MAA Accepted by UK MHRA for NSCLC Treatment
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has accepted the marketing authorization application (MAA) submitted by its US-based partner EQRx for sugemalimab in combination with chemotherapy as a first-line treatment of patients with metastatic non-small cell lung…
-
Ascletis Pharma Receives USPTO Notice for ASC10 Patent
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the Notice of Issuance from the United States Patent and Trademark Office (USPTO) for the patent application of oral viral polymerase inhibitor ASC10 and its derivatives, and their uses to treat multiple virus infections including SARS-CoV-2, monkeypox virus, and respiratory syncytial…
-
HutchMed Initiates Rolling NDA Submission for Elunate to US FDA
•
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the initiation of a rolling submission of a New Drug Application (NDA) to the US FDA for Elunate (fruquintinib) for the treatment of refractory metastatic colorectal cancer (CRC). HutchMed plans to complete the NDA submission in the first half of…
-
Luye Pharma’s Shandong Boan Biotechnology IPOs on Hong Kong Stock Exchange
•
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd has officially made an initial public offering (IPO) of 10.69 million shares to the Hong Kong Stock Exchange, priced at HKD 19.8 (USD 2.54) per share. This amounts to an HKD 212 million (USD 27.2 million) windfall…
-
Simcere Pharmaceutical Completes Enrollment for SIM0417 COVID-19 Drug Trial
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the completion of enrollment of 1,208 patients in a Phase II/III clinical study for its SIM0417, an oral COVID-19 drug candidate being co-developed with the Chinese Academy of Science’s Shanghai Institute of Materia Medica (SIMM) and the Wuhan Institute of Virology. Study…
-
Neurophth’s NFS-02 Gene Therapy Gets FDA IND Approval for LHON Treatment
•
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced obtaining Investigational New Drug (IND) approval from the US FDA for its second ophthalmology gene therapy, NFS-02 (rAAV2-ND1). The intended indication is Leber’s hereditary optic neuropathy (LHON) caused by the ND1 mutation. NFS-02: A Promising Gene Therapy for LHONNFS-02, a recombinant…
-
TG ImmunoPharma Gains FDA Approval for Phase I Study of Anti-PVRIG Antibody
•
China-based TG ImmunoPharma Co., Ltd has announced receiving the go-ahead from the US FDA to carry out a Phase I clinical study for its TGI-2/NM1F, a novel anti-PVRIG therapeutic antibody, in patients with advanced solid tumors. Currently, no drugs targeting PVRIG have been approved globally. TGI-2/NM1F: A Promising Anti-PVRIG Therapeutic…
